Clinical characteristics of thrombospondin type-1 domain-containing 7A-associated membranous nephropathy.
作者信息
Suzuki Tomo, Han Wei, Watanabe Shiika, Terashita Maho, Nakata Mayumi, Ichikawa Daisuke, Shirai Sayuri, Shibagaki Yugo
机构信息
Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Department of Nephrology, Kameda Medical Center, Chiba, Japan.
出版信息
Ren Fail. 2020 Nov;42(1):966-968. doi: 10.1080/0886022X.2020.1819318.
Abstract
摘要
相似文献
1
Clinical characteristics of thrombospondin type-1 domain-containing 7A-associated membranous nephropathy.含血小板反应蛋白1型结构域7A相关膜性肾病的临床特征
Ren Fail. 2020 Nov;42(1):966-968. doi: 10.1080/0886022X.2020.1819318.
2
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.特发性膜性肾病中含血小板反应蛋白1型结构域7A蛋白
N Engl J Med. 2015 Mar 12;372(11):1074-5. doi: 10.1056/NEJMc1500130.
3
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.特发性膜性肾病中含血小板反应蛋白1型结构域7A蛋白
N Engl J Med. 2015 Mar 12;372(11):1073. doi: 10.1056/NEJMc1500130.
4
Glomerular disease: thrombospondin type-1 domain-containing 7A-a new player in membranous nephropathy.肾小球疾病：含血小板反应蛋白1型结构域7A——膜性肾病中的新角色。
Nat Rev Nephrol. 2015 Feb;11(2):63. doi: 10.1038/nrneph.2014.227. Epub 2014 Dec 2.
5
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.特发性膜性肾病中的含血小板反应蛋白1型结构域7A
N Engl J Med. 2014 Dec 11;371(24):2277-2287. doi: 10.1056/NEJMoa1409354. Epub 2014 Nov 13.
6
Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy.多自身抗体特征与膜性肾病的临床结局。
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1762-1776. doi: 10.2215/CJN.02500220. Epub 2020 Nov 30.
7
Characterization of autoantibodies in primary membranous nephropathy and their clinical significance.原发性膜性肾病自身抗体的特征及其临床意义。
Expert Rev Clin Immunol. 2019 Feb;15(2):165-175. doi: 10.1080/1744666X.2019.1548934. Epub 2018 Nov 27.
8
Clinical and Histological Features of Phospholipase A2 Receptor-Associated and Thrombospondin Type-I Domain-containing 7A-Associated Idiopathic Membranous Nephropathy: A Single Center Retrospective Study from China.中国单中心回顾性研究：磷脂酶 A2 受体相关和血栓素型 1 域包含 7A 相关特发性膜性肾病的临床和组织学特征。
Med Sci Monit. 2018 Jul 22;24:5076-5083. doi: 10.12659/MSM.909815.
9
A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.PLA2R 和 THSD7A 在膜性肾病中的作用的新见解。
J Immunol Res. 2021 Jul 14;2021:8163298. doi: 10.1155/2021/8163298. eCollection 2021.
10
Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.抗含血小板反应蛋白1结构域7A自身抗体可诱发膜性肾病。
J Clin Invest. 2016 Jul 1;126(7):2519-32. doi: 10.1172/JCI85265. Epub 2016 May 23.
引用本文的文献
1
The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study.利珀他单抗治疗特发性膜性肾病的疗效和安全性：一项回顾性多中心队列研究。
Sci Rep. 2025 Jul 1;15(1):20567. doi: 10.1038/s41598-025-06046-1.
2
Comparison of the efficacy and impact on coagulation function of different rituximab dosage regimens in the treatment of membranous nephropathy.不同剂量利妥昔单抗治疗方案治疗膜性肾病的疗效及对凝血功能影响的比较
Am J Transl Res. 2025 Mar 15;17(3):1974-1984. doi: 10.62347/WQAB1378. eCollection 2025.
3
Histological transition from minimal change disease to THSD7A-associated membranous nephropathy in a patient receiving long-term steroid treatment: A case report.长期接受类固醇治疗的患者中微小病变病向 THSD7A 相关膜性肾病的组织学转变：病例报告。
Medicine (Baltimore). 2023 Oct 13;102(41):e35470. doi: 10.1097/MD.0000000000035470.
4
Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience.低剂量利妥昔单抗成功治疗难治性特发性膜性肾病：单中心经验
World J Clin Cases. 2023 Jan 26;11(3):566-575. doi: 10.12998/wjcc.v11.i3.566.
5
Spontaneous Remission of Thrombospondin Type-1 Domain-Containing-Associated Membranous Nephropathy.特发性血栓性血小板减少性紫癜相关性膜性肾病自发缓解。
Intern Med. 2021 Oct 1;60(19):3125-3128. doi: 10.2169/internalmedicine.6413-20. Epub 2021 Apr 12.
本文引用的文献
1
Membranous nephropathy associated with thrombospondin type-1 domain-containing 7A (THSD7A) in an adult woman with eosinophilia.一名成年女性伴嗜酸性粒细胞增多的血栓反应蛋白型 1 结构域包含 7A（THSD7A）相关膜性肾病。
CEN Case Rep. 2020 Feb;9(1):65-73. doi: 10.1007/s13730-019-00430-3. Epub 2019 Nov 8.
2
Expression of THSD7A in neoplasm tissues and its relationship with proteinuria.THSD7A 在肿瘤组织中的表达及其与蛋白尿的关系。
BMC Nephrol. 2019 Aug 23;20(1):332. doi: 10.1186/s12882-019-1489-5.
3
Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy.磷脂酶 A2 受体和血栓反应蛋白 1 型结构域包含 7A 在恶性肿瘤相关膜性肾病中的特征。
J Clin Pathol. 2019 Oct;72(10):705-711. doi: 10.1136/jclinpath-2019-205852. Epub 2019 Jun 26.
4
Refractory THSD7A membranous nephropathy with severe asthma related to eosinophilia
.难治性THSD7A膜性肾病伴与嗜酸性粒细胞增多相关的严重哮喘
Clin Nephrol. 2019 Aug;92(2):103-108. doi: 10.5414/CN109751.
5
Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy.血栓反应蛋白 1 型结构域包含蛋白 7A 相关膜性肾病的临床病理特征。
Virchows Arch. 2019 Jun;474(6):735-743. doi: 10.1007/s00428-019-02558-0. Epub 2019 Mar 14.
6
VEGF-A Links Angiolymphoid Hyperplasia With Eosinophilia (ALHE) to THSD7A Membranous Nephropathy: A Report of 2 Cases.VEGF-A 将血管淋巴样增生伴嗜酸性粒细胞增多症 (ALHE) 与 THSD7A 膜性肾病联系起来：2 例报告。
Am J Kidney Dis. 2019 Jun;73(6):880-885. doi: 10.1053/j.ajkd.2018.10.009. Epub 2018 Dec 13.
7
A Mechanism for Cancer-Associated Membranous Nephropathy.癌症相关性膜性肾病的一种机制。
N Engl J Med. 2016 May 19;374(20):1995-6. doi: 10.1056/NEJMc1511702.
8
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.特发性膜性肾病中的含血小板反应蛋白1型结构域7A
N Engl J Med. 2014 Dec 11;371(24):2277-2287. doi: 10.1056/NEJMoa1409354. Epub 2014 Nov 13.
9
Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy.在特发性膜性肾病中，Th2细胞因子增加并刺激B细胞产生IgG4。
Kidney Int. 2005 Jul;68(1):302-10. doi: 10.1111/j.1523-1755.2005.00415.x.
Zotero 插件